44 results on '"Watz Henrik"'
Search Results
2. Longitudinal Impact of Sputum Inflammatory Phenotypes on Small Airway Dysfunction and Disease Outcomes in Asthma
3. Non-typeable Haemophilus influenzae–Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial
4. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
5. Differential Impact of Low Fat-Free Mass in People With COPD Based on BMI Classifications: Results From the COPD and Systemic Consequences-Comorbidities Network
6. Small Airway Dysfunction Links Asthma Severity with Physical Activity and Symptom Control
7. COPD maintenance medication is linked to left atrial size: Results from the COSYCONET cohort
8. Inhaled long-acting muscarinic antagonists in asthma – A narrative review
9. Measurement of urinary Dickkopf-3 uncovered silent progressive kidney injury in patients with chronic obstructive pulmonary disease
10. Relationship between clinical and radiological signs of bronchiectasis in COPD patients: Results from COSYCONET
11. CAT score single item analysis in patients with COPD: Results from COSYCONET
12. Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial
13. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial
14. Left ventricular volume and wall stress are linked to lung function impairment in COPD
15. Compatibility of medication with PRISCUS criteria and identification of drug interactions in a large cohort of patients with COPD
16. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling
17. The revised GOLD 2017 COPD categorization in relation to comorbidities
18. Chronic obstructive pulmonary disease
19. Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD — A randomised, multicentre, crossover trial
20. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma
21. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline
22. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial
23. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD
24. Effects of beclomethason/formoterol and budesonide/formoterol fixed combinations on lung function and airway inflammation in patients with mild to moderate asthma – An exploratory study
25. Omalizumab in patients with allergic (IgE-mediated) asthma and IgE/bodyweight combinations above those in the initially approved dosing table
26. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale
27. Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD
28. Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD
29. HOPE-preservation of paraffin-embedded sputum samples–A new way of bioprofiling in COPD
30. Physical activity monitoring in COPD: Compliance and associations with clinical characteristics in a multicenter study
31. Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease
32. Physical Activity Is the Strongest Predictor of All-Cause Mortality in Patients With COPD: A Prospective Cohort Study
33. Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: A randomised controlled 6-week trial
34. Efficacy of the pan-selectin antagonist Bimosiamose on ozone-induced airway inflammation in healthy subjects – A double blind, randomized, placebo-controlled, cross-over clinical trial
35. Decreasing Cardiac Chamber Sizes and Associated Heart Dysfunction in COPD: Role of Hyperinflation
36. The Metabolic Syndrome in Patients With Chronic Bronchitis and COPD: Frequency and Associated Consequences for Systemic Inflammation and Physical Inactivity
37. In contrast to lung fibroblasts – no signs of senescence in skin fibroblasts of patients with emphysema
38. Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma
39. Neutrophil extracellular trap formation and extracellular DNA in sputum of stable COPD patients
40. Multi-analyte profiling of inflammatory mediators in COPD sputum – The effects of processing
41. The Impact of Stepwise Withdrawal of ICS on FEV1, mMRC, and SQRQ in Severe to Very Severe COPD Patients Treated With LAMA+LABA: The WISDOM Study
42. Exacerbation Risk Is Not Worse When ICS Are Withdrawn in a Stepwise Manner in Severe to Very Severe COPD Patients Receiving LAMA+LABA: The WISDOM Study
43. Metabolic Syndrome and Impaired Lung Function: Response
44. PEAK INSPIRATORY FLOW THROUGH THE ALMIRALL INHALER IN PATIENTS WITH MODERATE OR SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.